Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial
Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial
Shiro Imagama, Masashi Yamazaki, Masao Koda, Masayuki Miyagi et al.
Citations
18 citations
Journal
Stem Cell Research & Therapy
Topics
Spinal Cord Injury Research
Field-Weighted Citation Impact (FWCI)
7.65
article
Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial
Hiroshima University (JP), University of Tsukuba (JP), Hirosaki University (JP), Chiba University (JP), Yamaguchi University (JP), Wakayama Medical University (JP), Hamamatsu University School of Medicine (JP), Sendai Medical Center (JP), Spinal Injuries Center (JP), Nagoya University (JP), Kitasato University (JP), Dokkyo Medical University (JP), Tohoku Medical and Pharmaceutical University (JP)